Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00292396 | Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaque Psoriasis | PHASE2 | COMPLETED | 180 | — | — | Nov 1, 2005 | Apr 1, 2008 | Jan 18, 2013 | 24 | United States, Canada |
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | Anti IL-12 monoclonal antibody/ABT-874, up to 12 weeks, 200 mg every week for 12 weeks |
| 2 | ACTIVE_COMPARATOR | Anti IL-12 monoclonal antibody/ABT-874, 200 mg QOW for 12 weeks |
| 3 | ACTIVE_COMPARATOR | Anti IL-12 monoclonal antibody/ABT-874, 100 mg QOW in 12 weeks |
| 4 | ACTIVE_COMPARATOR | Anti IL-12 monoclonal antibody/ABT-874, 200 mg times 4 doses in 12 weeks |
| 5 | ACTIVE_COMPARATOR | Anti IL-12 monoclonal antibody/ABT-874, 200 mg times 1 dose in 12 weeks |
| 6 | PLACEBO_COMPARATOR | placebo, 12 doses |
| Name | Type | Description |
|---|---|---|
| Anti IL-12 monoclonal antibody/ABT-874 | DRUG | Please see Arm Description for intervention description and details. |
| placebo | DRUG | 12 doses |
Inclusion Criteria: * Subject was age 18 or older and in good health (Investigator discretion) with a recent stable medical history. * Subject had a clinical diagnosis of psoriasis for at least 6 months, and had moderate to severe plaque psoriasis Exclusion Criteria: * Subject had previously rece...